A000020 Stock Overview
Manufactures and sells pharmaceutical products in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Dongwha Pharm.Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩6,290.00 |
| 52 Week High | ₩10,760.00 |
| 52 Week Low | ₩5,950.00 |
| Beta | 1.09 |
| 1 Month Change | -5.98% |
| 3 Month Change | -20.88% |
| 1 Year Change | -36.59% |
| 3 Year Change | -56.47% |
| 5 Year Change | -22.73% |
| Change since IPO | 139.28% |
Recent News & Updates
Dongwha Pharm.Co.Ltd's (KRX:000020) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Nov 20
Dongwha Pharm.Co.Ltd's (KRX:000020) Promising Earnings May Rest On Soft Foundations
Mar 26Recent updates
Dongwha Pharm.Co.Ltd's (KRX:000020) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Nov 20Dongwha Pharm.Co.Ltd's (KRX:000020) Promising Earnings May Rest On Soft Foundations
Mar 26Is Dongwha Pharm.Co.,Ltd (KRX:000020) A Smart Pick For Income Investors?
Apr 28These 4 Measures Indicate That Dongwha Pharm.Co.Ltd (KRX:000020) Is Using Debt Safely
Mar 11Dongwha Pharm.Co.,Ltd (KRX:000020) Has A ROE Of 8.6%
Feb 22Is Dongwha Pharm.Co.Ltd's (KRX:000020) Share Price Gain Of 102% Well Earned?
Feb 07Should Dongwha Pharm.Co.,Ltd (KRX:000020) Be Part Of Your Dividend Portfolio?
Jan 23Is Dongwha Pharm.Co.,Ltd (KRX:000020) Popular Amongst Insiders?
Jan 08
Dongwha Pharm.Co.,Ltd (KRX:000020) Pays A ₩120 Dividend In Just Four Days
Dec 24We're Not Counting On Dongwha Pharm.Co.Ltd (KRX:000020) To Sustain Its Statutory Profitability
Dec 19Is Dongwha Pharm.Co.Ltd (KRX:000020) Using Too Much Debt?
Dec 04Can Dongwha Pharm.Co.,Ltd (KRX:000020) Improve Its Returns?
Nov 19Shareholder Returns
| A000020 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -2.0% | -1.7% | -3.7% |
| 1Y | -36.6% | 0.1% | -10.4% |
Return vs Industry: A000020 underperformed the KR Pharmaceuticals industry which returned 0.1% over the past year.
Return vs Market: A000020 underperformed the KR Market which returned -10.4% over the past year.
Price Volatility
| A000020 volatility | |
|---|---|
| A000020 Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A000020 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A000020's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1897 | 816 | Doh Yoon | www.dong-wha.co.kr |
Dongwha Pharm Co.,Ltd manufactures and sells pharmaceutical products in South Korea. It offers ethical products in the areas of alimentary system, antibiotic, cardiovascular/metabolic disease, NSAID/respiratory system, muscle relaxants/musculoskeletal system, nervous system, and dermatological/urinary system; OTC products in the areas of alimentary system, cold remedy, NSAID/respiratory system, dermatological, mouth and tooth, hepatic protectors, nutrients, tonics, topic analgesic, antihistamines, sore throat, and others; quasi drugs; health subsidiary foods; foods and drinks; and cosmetics.
Dongwha Pharm.Co.,Ltd Fundamentals Summary
| A000020 fundamental statistics | |
|---|---|
| Market cap | ₩174.35b |
| Earnings (TTM) | ₩7.67b |
| Revenue (TTM) | ₩428.48b |
22.7x
P/E Ratio0.4x
P/S RatioIs A000020 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A000020 income statement (TTM) | |
|---|---|
| Revenue | ₩428.48b |
| Cost of Revenue | ₩222.50b |
| Gross Profit | ₩205.98b |
| Other Expenses | ₩198.31b |
| Earnings | ₩7.67b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 276.81 |
| Gross Margin | 48.07% |
| Net Profit Margin | 1.79% |
| Debt/Equity Ratio | 14.2% |
How did A000020 perform over the long term?
See historical performance and comparisonDividends
2.9%
Current Dividend Yield65%
Payout RatioDoes A000020 pay a reliable dividends?
See A000020 dividend history and benchmarks| Dongwha Pharm.Co.Ltd dividend dates | |
|---|---|
| Ex Dividend Date | Dec 27 2024 |
| Dividend Pay Date | Apr 25 2025 |
| Days until Ex dividend | 5 days |
| Days until Dividend pay date | 124 days |
Does A000020 pay a reliable dividends?
See A000020 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 23:16 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dongwha Pharm.Co.,Ltd is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dodo Cheng | HSBC |